Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.
Publisher DOI
PubMed ID
39587300
Abstract
The androgen receptor (AR) signalling pathway has been intensively studied in the context of prostate cancer, where androgen deprivation therapy is part of the standard of care for metastatic disease. By contrast, fewer studies have investigated the impact and translational potential of targeting AR in other cancer types where it is also expressed and functional. In this Review, we discuss the current understanding of AR in non-prostatic cancer types and summarize ongoing AR-directed clinical trials. While different androgen levels contribute to sexual dimorphism in cancer, targeting the AR system could benefit both sexes and help overcome resistance to targeted therapies. However, a bimodal function of AR signalling, which suppresses stromal changes associated with the early stages of cancer development, also needs to be considered. Future research is necessary to scrutinize cellular and molecular mechanisms of action of AR in cancer cells and the tumour microenvironment, to develop selective modulators of AR activity, and to identify patients with non-prostatic cancer who might benefit from targeting this pathway. AR-directed manipulation of host immune cells may offer a promising therapeutic approach for many types of cancers.
Date Issued
2025-02
Publication Type
Article
Subject(s)
Language(s)
en
Author(s)
Dotto, G Paolo | |
Buckinx, An |
Additional Credits
Journal
Nature Reviews Cancer
Publisher
Nature Research
ISSN
1474-1768
1474-175X
Access(Rights)
restricted